Methylphenidate ameliorates depressive comorbidity in ADHD children without any modification on differences in serum...

Area of Science:

• Neuroendocrinology
• Pediatric Psychiatry

Background:

• Attention-deficit/hyperactivity disorder (ADHD) frequently co-occurs with other conditions, notably depressive symptoms.
• Melatonin, a key regulator of circadian rhythms, neurological function, and stress response, is implicated as a mediator in ADHD.

Purpose of the Study:

• To investigate serum melatonin variations and nocturnal excretion in ADHD subtypes.
• To assess the impact of methylphenidate on melatonin levels and ADHD symptomatology.

Main Methods:

• 136 children diagnosed with ADHD (DSM-IV-TR) were categorized using the Children's Depression Inventory (CDI).
• Serum melatonin and urinary metabolite levels were measured via radioimmunoassay (RIA) at baseline and after treatment.
• Factorial analysis was employed using STATA 12.0.

Main Results:

• Elevated serum melatonin was observed primarily in hyperactive-impulsive/conduct disordered (PHI/CD) ADHD subtype, independent of depressive symptoms.
• Methylphenidate treatment reduced comorbid depressive symptoms without altering serum melatonin.
• A decrease in 6-sulfatoxymelatonin excretion was noted in both ADHD subtypes following methylphenidate administration.

Conclusions:

• Increased serum melatonin in PHI/CD children may reflect partial restoration of neuroendocrine balance in untreated ADHD.
• Altered cerebral melatonin metabolism following methylphenidate treatment could contribute to its clinical efficacy.